Clinical Trial Update: Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating radiation therapy followed by tislelizumab and anlotinib as adjuvant or neoadjuvant therapy for Stage II-IIIA non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ji Yongling | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING